Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof

US9394363B2 · kind B2 · utility

Assignees

• Abb Vie Deutschland Gmbh & Co. KG · DE
• Abb Vie Inc. · US

Inventors

• Jijie Gu · Shrewsbury, US
• Chung-Ming Hsieh · Newton, US
• Zhen WU · Framingham, US
• Enrico L. DiGiammarino · Lindenhurst, US
• Feng Luo · Arlington Heights, US
• Gerard B. Fox · Barrington, US
• John E. Harlan · Lake Zurich, US
• Martin Schmidt · Frankfurt am Main, DE
• Ralf Loebbert · Speyer, DE
• Reinhold Mueller · Schifferstadt, DE
• Ulrich Ebert · Mannheim, DE
• Volker Nimmrich · Heidelberg, DE

Key dates

• Filing date: Nov 27, 2012
• Grant date: Jul 19, 2016
• Expiry date: Jul 29, 2033

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid β and advanced glycation-end-products.